You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 5, 2024

CLINICAL TRIALS PROFILE FOR SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Spironolactone And Hydrochlorothiazide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00224549 ↗ PHARES Study: Management of Resistant Hypertension Completed Assistance Publique - Hôpitaux de Paris Phase 4 2005-04-01 The purpose of this study is to assess the efficacy of two different treatment regimens for treating resistant hypertension previously uncontrolled with at least 3 antihypertensive treatments. The study hypothesis is that these two regimens (one based on increasing diuretics and the other based on increasing renin angiotensin system blockage) may not differ in terms of efficacy.
NCT00515021 ↗ Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed National Center for Research Resources (NCRR) Phase 4 2007-04-01 To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
NCT00515021 ↗ Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed Vanderbilt University Medical Center Phase 4 2007-04-01 To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
NCT00865124 ↗ Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 2008-09-01 Aldosterone is a significant mediator of cardiovascular injury associated with heart failure and the cardiovascular benefits of mineralocorticoid receptor blockade are additive to those of angiotensin converting enzyme inhibitors or angiotensin II (ANGII) receptor blockers. This study will test the hypothesis that mineralocorticoid receptor (MR) antagonists exert beneficial cardiovascular effects, specifically by decreasing vascular injury and improving vascular function. A randomized, double-blind study will be conducted, in which participants with Type 2 Diabetes Mellitus will undergo a series of assessments to test heart, blood vessel, and kidney function at baseline, and after 2 and 6 months of treatment with one of the following drugs: 1. spironolactone 2. hydrochlorothiazide (HCTZ) plus potassium 3. placebo In the event of insufficient funds, randomization to the placebo arm will be stopped and primary assessment of outcomes will occur at baseline and after 6 months of treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Spironolactone And Hydrochlorothiazide

Condition Name

Condition Name for Spironolactone And Hydrochlorothiazide
Intervention Trials
Hypertension 4
Acute Heart Failure 1
Acute Kidney Injury 1
Blood Pressure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Spironolactone And Hydrochlorothiazide
Intervention Trials
Hypertension 4
Metabolic Syndrome X 1
Congenital Abnormalities 1
Metabolic Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Spironolactone And Hydrochlorothiazide

Trials by Country

Trials by Country for Spironolactone And Hydrochlorothiazide
Location Trials
United States 12
Mexico 1
Thailand 1
Puerto Rico 1
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Spironolactone And Hydrochlorothiazide
Location Trials
Tennessee 2
Massachusetts 1
Virginia 1
Pennsylvania 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Spironolactone And Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Spironolactone And Hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Spironolactone And Hydrochlorothiazide
Clinical Trial Phase Trials
Completed 4
Recruiting 2
Terminated 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Spironolactone And Hydrochlorothiazide

Sponsor Name

Sponsor Name for Spironolactone And Hydrochlorothiazide
Sponsor Trials
Brigham and Women's Hospital 1
Biomedis International Ltd. 1
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Spironolactone And Hydrochlorothiazide
Sponsor Trials
Other 8
NIH 3
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.